XBiotech Inc. — Q2 2020 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2020. XBiotech is a pre-commercial biopharmaceutical company developing True Human monoclonal antibodies. Its reported 2020 revenue came from Janssen manufacturing and clinical-trial service agreements; it had no revenue in the comparable 2019 periods.
Financial performance
| Metric | Q2 2020 | Six months 2020 | Comparable 2019 |
|---|---|---|---|
| Revenue | $15.5 million | $28.2 million | None |
| Gross profit / margin | $2.3 million / 14.8% | $5.3 million / 18.8% | No revenue reported |
| Operating loss | $6.5 million | $8.7 million | $6.0 million / $11.8 million |
| Net loss | $6.8 million | $6.9 million | $5.9 million / $11.7 million |
| Net loss per share | $0.24 | $0.21 | $0.16 / $0.32 |
| Operating cash flow | Not stated for quarter | $(72.2) million | $(9.5) million |
Amounts are in U.S. dollars; financial statement amounts are in thousands unless otherwise indicated. Q2 revenue comprised $4.5 million manufacturing revenue and $11.0 million clinical-trial services revenue. Six-month revenue was $7.5 million and $20.7 million, respectively. Clinical-trial services revenue includes pass-through costs plus a 30% markup.
At June 30, cash and cash equivalents were $229.7 million, down from $714.6 million at year-end 2019. Current assets were $258.4 million and current liabilities $14.1 million. Total liabilities were $15.2 million; the filing reports no debt. The balance sheet also included a $75.0 million escrow receivable and $20.7 million accounts receivable. The company reported $343.6 million of shareholders’ equity.
Material changes and cash use
- Revenue began in 2020 under agreements associated with the December 2019 Janssen transaction; reported revenue is service and manufacturing revenue, not product sales.
- Six-month net loss improved from $11.7 million to $6.9 million, while Q2 net loss increased from $5.9 million to $6.8 million. Research and development expense declined year over year, partly because manufacturing and trial costs shifted to cost of goods sold following the Janssen agreements.
- General and administrative expense rose to $10.3 million for the first half, from $2.6 million. The company cited higher share-based compensation, a $2.7 million CEO bonus in June, and tender-offer-related professional and legal fees.
- Operating cash use included a $51.1 million income-tax payment relating to 2019. Financing cash use was $411.8 million, principally the February tender offer: XBiotech repurchased 14 million shares for approximately $420 million, or 32.67% of shares then outstanding. Employee option exercises generated $8.3 million.
- Cash and cash equivalents declined by $484.9 million in the first half. The filing also states that $75 million from the Janssen transaction is expected in 2021.
Outlook, risks, and notable items
- Management expects cash to be sufficient for at least one year from the report issuance date and said Janssen revenue is expected to support research and development over the next two years. It also expects significant operating losses for the foreseeable future and may never achieve profitability.
- The company expected to complete outstanding Janssen manufacturing volumes and return to normal manufacturing capabilities in Q3 2020, but cautioned that pandemic-related uncertainty could change that expectation. Syringe shortages delayed production; Janssen reduced an order and requested delayed shipments. $1.5 million was recorded as deferred revenue for unfinished volumes.
- COVID-19 risks include further supply-chain constraints, reduced Janssen orders, delays or disruptions to clinical trials and research, staffing and operational challenges, and potential adverse effects on revenue and liquidity. Management said COVID-19 had not materially adversely affected results or financial position as of June 30, 2020, but future effects were uncertain.
- XBiotech reported discovery and cell-line development progress for new anti-IL-1α antibodies, with a goal of re-entering clinical trials in 2021. It also began identifying lead antibody candidates for a COVID-19 therapy. These are development plans, not approved products or assured milestones.
- Management described a July publication reporting reduced brain damage in an experimental stroke model after anti-IL-1α treatment; the result is preclinical and does not establish clinical efficacy.
- Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter. It reported no material market-risk exposure requiring hedging.
Important facts for investors to verify
- Whether Janssen manufacturing orders, clinical-trial activity, and related revenue continued as expected after June 30, particularly following pandemic-related delays and order reductions.
- Whether the company achieved its stated Q3 2020 manufacturing normalization target and how the $1.5 million deferred revenue was subsequently recognized.
- Cash runway assumptions, future operating cash use, and timing and certainty of the expected $75 million Janssen payment in 2021.
- Progress and timing of the planned 2021 anti-IL-1α clinical studies, including any pandemic-related delays and the resources required.
- The composition and repeatability of G&A costs, including CEO compensation and elevated share-based compensation, and the effect of the tender offer on the share count.
- Whether the escrow receivable and accounts receivable were collected, and the extent of any continuing COVID-19 operational, clinical, or supply-chain impacts.